Category: Markets
Published: 2026-08-17T16:26:48.000Z
Levi & Korsinsky, LLP is alerting investors of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) about a pending securities class action. The lawsuit alleges that Regeneron made misleading statements regarding its Phase III Fianlimab-Libtayo Study, which led to a significant stock price drop. Investors who purchased REGN shares between August 1, 2025, and May 15, 2026, have until September 14, 2026, to apply for lead plaintiff appointment.
News summary curated and translated by CausifyMarket. Always consult original sources before making any financial decision.